Ex-Execs Blame FDA Rules In Off-Label Fraud Trial
By Brian Amaral ( June 7, 2016, 5:10 PM EDT) -- Former executives of Johnson & Johnson subsidiary Acclarent Inc. told a Massachusetts federal jury Tuesday that the real impetus for their trial on fraud charges is a government desire to crack down on off-label promotion, saying opaque and contradictory rules on off-label medical devices combined with bureaucratic infighting to hinder innovation....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.